<DOC>
	<DOCNO>NCT02404051</DOCNO>
	<brief_summary>This multi-center , randomize , open-label , parallel group study design evaluate efficacy safety fulvestrant follow , progression , examestane everolimus versus examestane everolimus follow , progression , fulvestrant postmenopausal woman HR+ HER2- LABC MBC whose disease progress NSAI adjuvant metastatic setting .</brief_summary>
	<brief_title>Fulvestrant EVerolimus Plus EXemestane Metastatic Breast Cancer</brief_title>
	<detailed_description>In study everolimus administer combination exemestane , irreversible steroidal aromatase inactivator demonstrate efficacy treatment postmenopausal patient ABC . Exemestane indicate adjuvant treatment postmenopausal woman HR+ EBC receive two three year tamoxifen switch exemestane completion total five consecutive year adjuvant hormonal therapy . It also indicate treatment ABC postmenopausal woman whose disease progress follow tamoxifen therapy ( USA ) follow antiestrogen therapy ( Europe ) . In 2011 , BOLERO-2 trial report ( 5 ; 33 ) significant benefit HR+ HER2- postmenopausal pretreated woman ABC set combine everolimus exemestane . In randomized , double-blind , placebo-controlled trial statistically significant improvement PFS add everolimus exemestane versus exemestane alone report . Adding everolimus determine 2.4-fold prolongation PFS 3.2 7.4 month lower risk cancer progression 56 % woman . These finding confirm independent assessment ( 4.1 vs. 11.0 month , risk reduction : 64 % ) . The QoL data show positive trend everolimus plus exemestane treatment arm .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>1 . Adult woman ( ≥ 18 year age ) LABC MBC amenable curative treatment surgery radiotherapy , refractory NSAI 2 . Histological cytological confirmation ER+ BC and/or PgR+ . 3 . Postmenopausal woman . 4 . Radiological objective evidence recurrence progression last systemic therapy prior randomization 5 . Patients must : At least one lesion accurately measure least one dimension ≥ 20 mm conventional image technique ≥ 10 mm spiral CT MRI Bone lesion : lytic mixed ( lytic + sclerotic ) absence measurable disease define . 6 . Adequate bone marrow coagulation accord RCP 7 . Adequate liver function , accord RCP 8 . Adequate renal function , accord RCP 9 . ECOG Performance Status ≤ 2 10 . Written inform consent 1 . HER2overexpressing patient local laboratory testing ( IHC3+ stain situ hybridization positive ) . 2 . Patients receive chemotherapy MBC 3 . Patients receive one NSAI treatment LABC MBC 4 . Premenopausal , pregnant , lactating woman . 5 . Known hypersensitivity mTOR inhibitor 6 . Patients rare hereditary problem galactose intolerance , Lapp lactase deficiency glucose galactose malabsorption . 7 . Radiotherapy within four week prior enrollment 8 . Currently receive hormone replacement therapy , unless discontinue prior enrollment . 9 . Patients receive concomitant immunosuppressive agent chronic corticosteroid use , time study entry except case 10 . Patients symptomatic visceral disease need urgent disease control 11 . Symptomatic brain CNS metastases . 12 . Patients known history HIV seropositivity . 13 . Active , bleed diathesis , oral antivitamin K medication ( except case ) . 14 . Any severe / uncontrolled medical condition : Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤6 month prior enrollment , serious uncontrolled cardiac arrhythmia Uncontrolled diabetes define fast serum glucose &gt; 1.5 × ULN Acute chronic , active infectious disorder Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption study treatment ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome ) Inability swallow oral medication Significant symptomatic deterioration lung function . 15 . Hepaticrelated exclusion criterion : History liver disease , cirrhosis chronic active hepatitis B C. Presence Hepatitis B surface antigen ( HbsAg ) and/or Hepatitis B Virus Deoxyribonucleic acid ( HBVDNA ) Presence antiHCV and/or HCVRNAPCR History , current alcohol misuse/abuse within past 12 month Patients treat drug recognize strong inhibitor inducer isoenzyme CYP3A within last 5 day prior enrollment . History noncompliance medical regimen . Patients unwilling unable comply protocol 16 . Patients treat drug recognize strong inhibitor inducer isoenzyme CYP3A 17 . History noncompliance medical regimen . 18 . Patients unwilling unable comply protocol . Screening hepatitis B Prior enrollment , peculiar patient test hepatitis B viral load serologic marker , , HBVDNA , HBsAg , HBsAb , HBcAb : Screening hepatitis C Patients follow risk factor hepatitis C test</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>HER2Negative</keyword>
	<keyword>hormone receptor positive ( HR+ )</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Locally Advanced</keyword>
	<keyword>fulvestrant</keyword>
	<keyword>everolimus</keyword>
	<keyword>exemestane</keyword>
</DOC>